Amrutanjan Health Care Limited
Valuation (88/100) does the heavy lifting; momentum (11/100) is the drag.
Buy zoneAmrutanjan Health Care Limited earns a Hold from StocksWizard, with a blended score of 58/100. On 25.4x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. It's sitting close to its 52-week low of ₹485.38. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. It clears 10 of 13 investability checks, with durability 65, valuation 76 and momentum 11 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹554.01.
1-year price
EOD · 2026-09-1452-week range
-35.25% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold58Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 16.6%
- Pass: Low debt (D/E < 0.5): 0.00x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 11%
- Pass: Earnings growing: 7%
- Pass: Net margin ≥ 10%: 11.5%
- Pass: Current ratio > 1.5: 2.31
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 8.02
- Fail: Piotroski ≥ 7: 2/9
Shareholding
- Promoter49.2%
- Institutions12.1%
- Public & other38.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 8.02.
Opportunities
- Trading in our value buy zone versus sector peers.
- Well off its 52-week high — possible mean-reversion.
- Trades ~41% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
- Weak Piotroski score (2/9).
About Amrutanjan Health Care Limited
Amrutanjan Health Care manufactures and distributes ayurvedic pain balms, women's hygiene products, beverages, and other consumer goods across India and internationally. Its product portfolio includes pain management items such as balms, roll-ons, patches and sprays; dental pain gel; corn caps; hand sanitizer under the NOGerms brand; and fruit and rehydration beverages.
Amrutanjan Health Care Limited — frequently asked questions
Is Amrutanjan Health Care Limited a buy, hold or sell?
StocksWizard currently rates Amrutanjan Health Care Limited (AMRUTANJAN) a Hold, based on a blended score of 58/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Amrutanjan Health Care Limited's fair value?
Our blended DCF and relative-valuation model estimates Amrutanjan Health Care Limited's fair value at about ₹692.51, versus a current price of ₹490.95 — roughly 41% upside. On that basis the stock looks undervalued by 41%.
Is Amrutanjan Health Care Limited financially healthy?
Amrutanjan Health Care Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has Amrutanjan Health Care Limited's share price performed?
Amrutanjan Health Care Limited is down 11% over three months, and last traded at ₹490.95. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.